Ma_2024_J.Ethnopharmacol__119016

ETHNOPHARMACOLOGICAL RELEVANCE: Alzheimer's disease (AD) is a common type of neurodegenerative disease with the beta-amyloid plaques (Abeta) deposition. Previously, Dengzhan Shengmai capsule (DZSM) has been shown to reduce the pathology associated with AD, but the underlying mechanism is unclear. AIM OF STUDY: This study investigated the potential mechanisms of DZSM against AD. MATERIALS AND METHODS: The six-month-old wild-type male mice and APP/PS1 double transgenic male mice were administered 0.9 % saline or DZSM for 8 weeks by gavage. Open field test, new object recognition test, and Morris Water maze test were used to assess spatial learning and memory. Abeta plaques in brains were visualized using ThT staining. Nissl staining, TUNEL staining, and western blot analyses were used to detect the neuronal function and apoptosis level. The superoxide dismutase (SOD), glutathione peroxidase assay kit (GSH-Px), and malondialdehyde (MDA) kits were performed to assess oxidative stress levels. Then, immunofluorescence and western blot analysis were applied to evaluate ER stress pathway protein levels. Finally, HT22 cells were treated by Abeta(1-42) with or without DZSM medicated serum. Cell viability was assessed using the CCK-8 assay, and western blot analysis was applied to evaluate ER stress pathway protein levels. RESULTS: Open filed test, new object recognition test and Morris Water maze test showed that DZSM restored cognitive disorders in APP/PS1 mice. Immunohistochemistry and Thioflavin T staining results indicated that DZSM reduced Abeta plaques in the brain. Deeper and denser Nissl bodies were found in APP/PS1 mice after DZSM administration. Besides, APP/PS1 mice treated with DZSM showed a lower level of TUNEL and Bax/Bcl-2 ratio. DZSM improved the acetylcholine (ACh), choline acetyltransferase (ChAT), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) activity while reducing acetylcholinesterase (AChE) and malondialdehyde (MDA) activity. In addition, the levels of ER stress pathway containing Phospho-PKR-like ER kinase (P-PERK), phosphorylate eukaryotic initiation factor 2 (P-eIF2alpha), activating transcription factor 4 (ATF4), glutamine-rich protein 1 (QRICH1), phosphorylate inositol-requiring protein 1alpha (P-IRE1alpha), the spliced form of X-box binding protein 1 (XBP1s), activating transcription factor-6 (ATF6) and C/EBP homologous binding protein (CHOP) were decreased by DZSM. CCK-8 results indicated that DZSM medicated serum played cytoprotective effects on Abeta(1-42)-induced HT22 cells. Western blot results suggested DZSM possibly inhibited ER stress pathways in Abeta(1-42)-induced HT22 cells. CONCLUSION: The potential protective mechanism of DZSM on cognitive impairment in AD might be related to ER stress pathways.